ALISO VIEJO, Calif.--(BUSINESS WIRE)--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms.

加利福尼亚州ALISO VIEJO——（商业新闻短讯）——全球神经血管公司MicroVention，Inc.，Terumo Corporation的全资子公司，今天宣布LVIS™EVO™腔内支持装置现已在美国上市，用于治疗宽颈颅内动脉瘤。

LVIS EVO has been available in Europe since 2019 and over 12,000 units have been sold. LVIS EVO is the first fully visible coil-assist-intracranial stent available in the US Market..

自2019年以来，LVIS EVO已在欧洲上市，已售出12000多辆。LVIS EVO是美国市场上第一个完全可见的线圈辅助颅内支架。。

LVIS EVO delivers enhanced visualization, optimized opening and precise placement with DFT wire construction and advanced braid design. With enhanced visualization, LVIS EVO provides wall apposition confirmation. The entire body of the stent is fully visible under fluoroscopy. The optimized braid angle allows for improved device opening along the entire length of the device.

LVIS EVO通过DFT导线结构和先进的编织设计，提供了增强的可视化、优化的开口和精确的放置。通过增强的可视化，LVIS EVO提供了墙并置确认。在透视下，支架的整个身体都是完全可见的。优化的编织角度允许沿着器件的整个长度改进器件开口。

With precise placement, LVIS EVO offers controlled delivery and development, as well as the ability to resheath the device up to eighty percent of the device length. The entire LVIS EVO portfolio is compatible with MicroVention’s Headway™ 17 Advanced Microcatheter and MicroVention’s Scepter C™ and Scepter XC™ Occlusion Balloons..

通过精确的放置，LVIS EVO提供了受控的交付和开发，并且能够将设备重新固定到设备长度的80%。整个LVIS EVO产品组合与MicroVention的Headway™17高级微导管以及MicroVention的Scepter C™和Scepter XC™闭塞气球兼容。。

“I’ve really enjoyed getting to use and know EVO. With improved visibility and the ability to shelf the stent across the aneurysm neck, it’s become my tool-of-choice for stent-assisted coiling,” said Dr. Charles Matouk, Vice Chair of the Department of Neurosurgery at Yale University.

耶鲁大学神经外科副主任Charles Matouk博士说：“我非常喜欢使用和了解EVO。随着能见度的提高和支架跨越动脉瘤颈部的能力，它已成为我支架辅助卷绕的首选工具。”。

“Today’s announcement underscores MicroVention’s commitment to delivering groundbreaking solutions for hemorrhagic stroke treatment,” said Carsten Schroeder, President and CEO of MicroVention, Inc. “MicroVention continues to lead the way in both hemorrhagic and ischemic stroke care. This achievement is a testament to our collaboration with leading physicians worldwide.

MicroVention，Inc.总裁兼首席执行官卡斯滕·施罗德（CarstenSchroeder）表示：“今天的宣布突显了MicroVention致力于为出血性中风治疗提供开创性的解决方案。MicroVention在出血性和缺血性中风护理方面继续处于领先地位。这一成就证明了我们与全球领先医生的合作。

By identifying the evolving needs in patient care and transforming those insights into innovative technologies, we are able to save lives and improve outcomes.”.

通过确定患者护理中不断变化的需求并将这些见解转化为创新技术，我们能够挽救生命并改善结果。”。

Indications for Use (US):

使用说明（美国）：

LVIS EVO device is indicated for use with neurovascular embolization coils in patients ≥ 18 years of age for the treatment of wide-neck (neck width ≥ 4 mm or dome to neck ratio < 2) saccular intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 4.5 mm.

LVIS EVO装置适用于≥18岁患者的神经血管栓塞线圈，用于治疗由直径≥2.0 mm且≤4.5 mm的母血管引起的宽颈（颈宽≥4 mm或穹窿颈比<2）囊状颅内动脉瘤。

About MicroVention, Inc.

关于MicroVention，Inc。

Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases.

MicroVention成立于1997年，开发和销售能够或显着改善脑血管疾病治疗的医疗设备。2006年，总部位于日本东京的全球大型医疗器械公司Terumo Corporation收购了MicroVention旗下的家族企业。Terumo收购MicroVention使两家公司能够利用其独特的专有技术，更加专注于治疗脑血管疾病。

Headquartered in California, MicroVention products are today sold in more than seventy countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California and San José, Costa Rica. For more information on MicroVention, please visit www.microvention.com..

总部位于加利福尼亚州的MicroVention产品今天通过直销组织和战略分销合作伙伴关系在70多个国家销售。制造工厂位于加利福尼亚州的Aliso Viejo和哥斯达黎加的圣何塞。有关MicroVention的更多信息，请访问www.MicroVention.com。。

About Terumo Corporation

关于Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to 'Contributing to Society through Healthcare' for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions.

Terumo（东京证交所代码：4543）是全球医疗技术的领导者，100年来一直致力于“通过医疗保健为社会做出贡献”。Terumo总部位于东京，在全球运营，在全球拥有28000多名员工，为160多个国家和地区提供创新的医疗解决方案。

The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments.

该公司最初是一家日本温度计制造商，此后一直支持医疗保健。现在，其广泛的业务组合包括血管介入和心脏外科解决方案、输血和细胞治疗技术，以及输血系统、糖尿病护理和腹膜透析治疗等日常临床实践所必需的医疗产品。

Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information on Terumo, please visit www.terumo.com/about/profile..

Terumo将进一步努力为患者、医疗专业人员和整个社会创造价值。有关Terumo的更多信息，请访问www.Terumo.com/about/profile。。

** Editor’s Note: For a Clinical Glossary of Terms, please visit https://www.microvention.com/clinical-education/glossary.

**编者按：有关临床术语表，请访问https://www.microvention.com/clinical-education/glossary.